Evidence map›Paper›PMID 26697427›Full record

ArticleFrontiers in cell and developmental biology2015

Stem Cell Markers in Neuroblastoma-An Emerging Role for LGR5.

Helen Forgham, Darren Johnson, Noel Carter, Stephany Veuger, Jane Carr-Wilkinson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Cancer stem cells in neuroblastoma therapy resistance.Cancer drug resistance (Alhambra, Calif.) · 2019
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Helen ForghamCancer Biology Group, Department of Pharmacy, Health and Well Being, Cancer Biology and Therapeutics, Faculty of Applied Sciences, University of Sunderland Sunderland, UK ; Children's Cancer Institute, University of New South Wales Sydney, NSW, Australia.
Darren JohnsonCancer Biology Group, Department of Pharmacy, Health and Well Being, Cancer Biology and Therapeutics, Faculty of Applied Sciences, University of Sunderland Sunderland, UK.
Noel CarterCancer Biology Group, Department of Pharmacy, Health and Well Being, Cancer Biology and Therapeutics, Faculty of Applied Sciences, University of Sunderland Sunderland, UK.
Stephany VeugerCancer Biology Group, Department of Pharmacy, Health and Well Being, Cancer Biology and Therapeutics, Faculty of Applied Sciences, University of Sunderland Sunderland, UK.
Jane Carr-WilkinsonCancer Biology Group, Department of Pharmacy, Health and Well Being, Cancer Biology and Therapeutics, Faculty of Applied Sciences, University of Sunderland Sunderland, UK ; Paediatric Oncology and Haematology, Newcastle Cancer Centre at The Northern Institute for Cancer Research, Newcastle University Newcastle Upon Tyne, UK.
University of Sunderland · GBUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognostic value of cancer stem cell markers in various cancer subtypes is a well documented research area. Our findings show that the stem cell marker Lgr5 is associated with an aggressive phenotype in neuroblastoma. Here, we discuss these findings within the context of recent studies in several cancers such as lung, colorectal and intestinal cancer, glioblastoma and ewing's sarcoma. Neuroblastoma continues to be an elusive disease, due to its heterogeneous presentation ranging from spontaneous regression to aggressive metastatic disease and intertwined genetic variability. Currently, the most significant prognostic marker of high risk disease and poor prognosis is amplification of the MYCN oncogene, which is found in approximately 25% of cases (Huang and Weiss, 2013). With this in mind, there is still much to learn about the driving mechanisms of this aggressive pediatric tumor. Neuroblastoma development is thought to be the result of aberrant differentiation of the cell of origin, embryonic neural crest cells which then migrate and invade during the developmental stage (Joshi et al., 2007). Aberrant cells are those which would, under normal conditions form the mature tissues of the sympathetic ganglia and adrenal medulla. Tumors are known to develop indiscriminately along the radius of the sympathetic ganglia, although it is well established that the adrenal glands are fundamentally the most common primary site (Jessen and Mirsky, 2005).

Indexed as

chemoresistanceLGR5neuroblastomarelapse

Identifiers

PMID26697427
PMCPMC4667032
OpenAlexW2246964591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.